Login to Your Account



ODAC Gives Hesitant Support to Talon's ALL Drug Marqibo

By Mari Serebrov
Washington Editor

Thursday, March 22, 2012
Although members of the FDA's Oncologic Drugs Advisory Committee (ODAC) were admittedly underwhelmed Wednesday by the data for Talon Therapeutics Inc.'s Marqibo, they voted 7 to 4, with two abstentions, that the drug demonstrated a favorable risk-benefit profile as a third-line treatment for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription